Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Eksterne analyser

Boule Diagnostics: Beat driven by cost savings on opex - ABG

Boule Diagnostics

Dette er en ekstern analyse og afspejler ikke nødvendigvis vores perspektiv eller værdier.

Download analyse (PDF)
Adj. EBIT +85% vs ABGSCe
Soft cash flow generation
Estimates likely up 10% on adj. EBIT


Q4 results

Net sales came at SEK 143.2m (+2% vs. ABGSCe 140.6m) with organic growth of -1.8% (ABGSCe -4.3%). The gross margin was 44.6% (ABGSCe 47.1%). Q4 adj. EBIT of SEK 19.5m (+85% vs. ABGSCe 10.5m). The beat on adj EBIT was driven by higher sales and lower underlying opex. The positive deviation on sales relates mainly to higher Instrument sales, driven by a larger number of instruments but at a lower ASP. Instrument sales in Q4 was SEK 41.0m (+24% vs. ABGSCe 33.2m) and total consumables sales was SEK 87.2m (-7% vs. ABGSCe 93.9m). The NRI of -14.8m (ABGSCe 0m) relates to restructuring charges of -7.6m and a write down of SEK 7.2m related to assets in Russia. Operating cash flow of SEK 15.1m was lower than expected (ABGSCe 35.3m).
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.